Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.

Nature communications - 19 Feb 2016

Ramirez Michael, Rajaram Satwik, Steininger Robert J, Osipchuk Daria, Roth Maike A, Morinishi Leanna S, Evans Louise, Ji Weiyue, Hsu Chien-Hsiang, Thurley Kevin, Wei Shuguang, Zhou Anwu, Koduru Prasad R, Posner Bruce A, Wu Lani F, Altschuler Steven J

Abstract excerpt

Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a 'persister' state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 26891683
DOI: 10.1038/ncomms10690
PMCID: PMC4762880

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.PMID 26891683Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read ↗

Drug-induced colorectal cancer persister cells show increased mutation rateSemantic proximity Read ↗

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.Semantic proximity Read ↗

Cancer drug-tolerant persister cells: from biological questions to clinical opportunitiesSemantic proximity Read ↗

A Mathematical Model of Persister Cell Plasticity and Its Impact on Adaptive Cancer TherapySemantic proximity Read ↗

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for TherapySemantic proximity Read ↗

Drug-Tolerant Persister Cells in Cancer Therapy ResistanceSemantic proximity Read ↗

Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Semantic proximity Read ↗

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.